International Journal of Tropical Medicine
ISSN: Online 1818-779XISSN: Print 1816-3319
104
Views
12
Downloads
Perspective and Practices Amongst the HCP’s (Diabetes) Towards Quality of Life (QoL) and Antidiabetic Management Strategies in T2DM: Survey Across India
Saptarshi Bhattacharya, Ameya Sudhakar, Priti Jayantilal Sanghavi, Ameet Rathod and Kunal Khobragade
Page: 148-153 | Received 01 Oct 2024, Published online: 09 Nov 2024
Full Text Reference XML File PDF File
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease and reported to have detrimental effect on quality of life. QoL is an important parameter in diabetes treatment modality. Multiple guidelines such as the American Diabetes Association 2019 guideline recommend oral antidiabetic drugs (OADs) such as sulfonylureas to be used as monotherapy (if metformin is not tolerated) or as combination therapy. As per the meta‐analysis, newer sulfonylureas like Glimepiride and Gliclazide are related with a lower chance of cardiovascular‐related and all‐cause mortality than other sulfonylureas. This survey was planned to analyze the perspective and practices of Consulting Physicians (CP’s) and Endocrinologist’s (Endo’s) while treating T2DM with focus on Gliclazide (newer SU), glucose monitoring tests and quality of life. This questionnaire‐based survey was carried out in 2023 among CP’s and Endo’s across India. A pre‐validated questionnaire was administered through personal interviews of participating CP’s and Endo’s. In this survey a total of 1491 CP’s and Endo’s participated. 61% CP’s and Endo’s chose glycemic control as the major factor while selecting oral antidiabetics. While considering QoL in T2DM, 72% of CP’s and Endo’s suggested re‐evaluating patients for oral antidiabetic selection routinely (as per patients ’clinical and laboratory parameters). While 56% of CP’s preferred to refer their patients for nutritionist opinion in dietary adjustment. 76.5% of CP’s strongly agreed that it is important to consider patients’ opinion while selecting OAD’s. 75% CP’s and Endo’s suggested that they prefer Sulfonylureas as add‐on therapy with alpha glucosidase inhibitors (AGI) in PPHG. 95% CP’s prefer Gliclazide+Dapagliflozin + Metformin combination particularly for tight glycemic control and 93% of CP’s prefer Gliclazide+Linagliptin combination as a safe measure for patients with renal disorders. This comprehensive survey highlighted the CP’s and Endo’s perspectives and practices in the management of type 2 diabetes mellitus (T2DM) related to quality of life. It was concluded that Gliclazide, a modern sulfonylurea has emerged as an affordable alternative after administration of an alpha‐glucosidase inhibitor (AGI) to control post prandial hyperglycemia (PPHG), also it was well received by patients and majority of CP’s and Endo’s because of better Quality of life (QoL). Most preferred combination of Gliclazide was with Dapagliflozin and Metformin to achieve tight glycemic control, whereas in T2DM patients with renal impairment, Linagliptin was found to be most preferred add‐on DPP4i with Gliclazide to control hyperglycemia.
How to cite this article:
Saptarshi Bhattacharya, Ameya Sudhakar, Priti Jayantilal Sanghavi, Ameet Rathod and Kunal Khobragade. Perspective and Practices Amongst the HCP’s (Diabetes) Towards Quality of Life (QoL) and Antidiabetic Management Strategies in T2DM: Survey Across India.
DOI: https://doi.org/10.36478/10.36478/makijtm.2024.4.148.153
URL: https://www.makhillpublications.co/view-article/1816-3319/10.36478/makijtm.2024.4.148.153